News
-
-
PRESS RELEASE
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and updates on NDA submissions for icotrokinra and rusfertide, as well as progress in clinical trials for PN-881 and IND-enabling studies for PN-477sc and PN-477o -
-
REGULATED PRESS RELEASE
Merger by absorption of the French company Interparfums Holding SAS by the French company Interparfums SA
French company Interparfums SA plans merger by absorption with Interparfums Holding SAS. AMF decides no public offer needed, General Meeting on December 17, 2025, details available online -
PRESS RELEASE
ACQUISITION DE 97,68% DE LA SOCIÉTÉ DE TAYNINH SUIVIE D'UNE OFFRE PUBLIQUE D'ACHAT SIMPLIFIÉE (SANS INTENTION DE RETRAIT OBLIGATOIRE) AU PRIX DE 0,11EUR PAR ACTION
Unibail-Rodamco-Westfield cède sa participation dans Société de Tayninh à trois investisseurs. Projet d'offre publique d'achat à venir -
-
PRESS RELEASE
Cell Impact and thyssenkrupp Automation Engineering have entered a cooperation agreement
Cell Impact and thyssenkrupp Automation Engineering enter Strategic Cooperation Agreement for Joint Market Success in Hydrogen field, focusing on flow plates and manufacturing processes for fuel cells and electrolyzers -
-
-